News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cambria Biosciences' Chemical Genetics Platform is Featured in Nature Article Describing a New Pharmaceutical Mode of Action



3/13/2008 8:45:49 AM

WOBURN, Mass.--(BUSINESS WIRE)--Cambria Biosciences, a privately held biopharmaceutical company, today announced that it has co-authored an article with partner Novartis Animal Health Inc. which was published in the March 13 edition of Nature. The study describes Novartis’ discovery of a new anthelmintic compound effective against parasitic nematode strains resistant to currently available treatments. Its unique mode of action was elucidated by Cambria’s chemical genetics platform, which identified a nematode-specific protein whose biological function had not been previously studied. This successful work also led to a development milestone payment from Novartis to Cambria as part of an existing collaboration between the two companies.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES